Analysts at Oppenheimer are out with a report this morning upgrading shares of Pier 1 Imports, Inc. (PIR) with an ‘Outperform‘ from ‘Perform‘ rating. The firm set its price target for the company at $20.
Pier 1 Imports Inc. shares are currently priced at 16.26x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s 21.13x earnings multiple. Ticker has a forward P/E of 15.67 and t-12 price-to-sales ratio of 0.65. EPS for the same period is $0.88.
In the past 52 weeks, shares of Fort Worth Texas-based company have traded between a low of $11.38 and a high of $19.83 and are now at $14.24. Shares are down 29.94% year-over-year and 12.58% year-to-date.
Biogen Idec Inc. (BIIB) was reiterated an ‘Overweight’ by Piper Jaffray analysts on Friday. The broker also raised its price target on the stock to $500 from $421.
Biogen Idec Inc. shares are currently priced at 38.20x this year’s forecasted earnings. Ticker has a PEG and forward P/E ratio of 1.42 and 23.69, respectively. Price/sales for the same period is 10.49 while EPS is $12.37. Currently there are 17 analysts that rate BIIB a ‘Buy’, 8 rate it a ‘Hold’. No analyst rates it a ‘Sell’. BIIB has a median Wall Street price target of $429 with a high target of $500.
In the past 52 weeks, shares of Cambridge, Massachusetts-based company have traded between a low of $272.02 and a high of $480.13 and are now at $472.52. Shares are up 23.90% year-over-year and 27.75% year-to-date.
Lennar Corp. (LEN) was reiterated as ‘Equal Weight’ with a $45 from $42 price target on Friday by Barclays.
Lennar shares recently gained $1.48 to $51.13. In the past 52 weeks, shares of Miami, Florida-based company have traded between a low of $35.74 and a high of $51.93. Shares are up 20.57% year-over-year and 10.90% year-to-date.
Celgene Corporation (CELG) rating of ‘Overweight’ was reiterated today at Piper Jaffray with a price target increase of $144 from $135 (versus a $125.33 previous close).
CELG shares recently gained $1.46 to $126.79. The stock is up more than 66.18% year-over-year and has gained roughly 12% year-to-date. In the past 52 weeks, shares of Summit, New Jersey-based biopharmaceutical company have traded between a low of $66.85 and a high of $129.06.
Celgene Corporation closed Thursday at $125.33. The name has a total market cap of $101.51 billion.
Nike, Inc. (NKE) was reiterated as ‘Buy’ and the price target was increased to $110 from $102 at Deutsche Bank (DB).
Nike shares are currently priced at 30.57x this year’s forecasted earnings, which makes them expensive compared to the industry’s 18.55x earnings multiple. The company’s current year and next year EPS growth estimates stand at 19.50% and 13.80% compared to the industry growth rates of 1.80% and 15.20%, respectively. NKE has a t-12 price/sales ratio of 2.85. EPS for the same period registers at $3.36.
Nike shares have advanced 5.32% in the last 4 weeks and 5.79% in the past three months. Over the past 5 trading sessions the stock has gained 1.32%. Shares of Nike, Inc., which are currently valued at $88.70 billion, are up 25.71% year-over-year and 2.56% year-to-date.